MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in cash, plus one non-tradable contingent value right (“CVR”) per share offering milestone-based payments of up to $1.00 per share. As detailed below, the sales price is below the price targets for SCPH of multiple Wall Street analysts covering SCPH prior to the announcement (s ...

MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.The deal marks MannKind’s strategic expansion into cardiorenal medicine, establishing its cardiometabolic business alongside its orphan lung division. It is also made possible on the heels of MannKind’s $500 million strategic financing agreement with Blackstone. ScPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering furos ...

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals’ 90 trading day VWAP, and ...

Core Insights - scPharmaceuticals Inc. has received five Notices of Allowance from the USPTO for patent applications related to its furosemide formulation, SCP-111, which is expected to have a supplemental NDA filed this quarter [1][2] - The additional patent protection is seen as a strategic achievement that enhances the company's intellectual property portfolio and supports the development of next-generation formulations [2] Company Overview - scPharmaceuticals is focused on advancing cardiorenal care through innovative treatments that address unmet patient needs [3] - The company's mission includes becoming a leading advocate for patient-centric cardiorenal care and improving global health through specialized approaches [4]

Financial Data and Key Metrics Changes - In Q2 2025, the company generated $16 million in net revenue, representing a 99% increase compared to Q2 2024 [5] - Approximately 20,200 doses of Furosex were filled, marking a 117% increase over Q2 2024 and a 45% increase over Q1 2025 [6] - The gross to net discount for Furosex in Q2 2025 was approximately 27%, with an anticipated increase to around 30% in Q3 2025 [15][16] - The company ended Q2 2025 with $40.8 million in cash and cash equivalents, down from $75.5 million at the end of 2024 [16] Business Line Data and Key Metrics Changes - The majority of the increase in doses shipped came from cardiology, while nephrology had just started to contribute [6] - The company launched Feroxix into nephrology in late April 2025, with a faster uptake observed compared to the cardiology launch [7] - The number of unique prescribers reached approximately 4,700, with expectations for steady growth as the company expands further into nephrology [12] Market Data and Key Metrics Changes - The growing number of Part D patients reaching their out-of-pocket maximums positively impacted Q2 performance [8] - The company anticipates continued growth in the IDN business segment, which has been performing above internal expectations [9][14] Company Strategy and Development Direction - The company remains optimistic about Furosex's future, particularly with the expanded CKD indication, favorable Part D dynamics, and the launch of the auto injector [11] - The proposed ambulatory specialty model by CMS is expected to enhance the management of heart failure and could provide a significant tailwind for Furosex [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercialization and marketing of Furosex, highlighting key growth drivers such as nephrology uptake and IDN business advancements [6][9] - The company is focused on reaching profitability and is evaluating impacts of tariffs, FX fluctuations, and increased COGS [34] Other Important Information - The company is on track for the submission of its sNDA for the auto injector in the current quarter, which is expected to significantly reduce COGS [10] Q&A Session Summary Question: Can you talk about the growth in cardiology and Class IV heart failure patients? - Management noted that fill rates increased in Q2 and anticipate continued growth in Q3 and Q4, driven by lower co-pays [21][22] Question: What are the early learnings from the CKD launch? - The nephrology launch is progressing well, with faster adoption rates compared to cardiology, and nephrologists tend to write larger prescriptions [25][33] Question: Can you provide details on the CKD launch trajectory and cash runway? - The majority of doses shipped in Q2 were for heart failure, with nephrology expected to have a meaningful impact starting in Q3. The company has access to additional capital if needed [31][34] Question: What is the timeline for the ASM program and its implementation? - The ASM program is anticipated to roll out in January 2027, with data collection starting then and implementation affecting payments in 2028 [37][39] Question: How has the Medicare Part D redesign impacted the business? - The redesign has shifted from a headwind to a tailwind, contributing to significant growth in new prescriptions written [42][44]

Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of inc ...

Exhibit 99.1 scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as ...

scPharmaceuticals, Inc. (SCPH) shares soared 8.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 35.3% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the initial sales uptake of the company's marketed product, Furoscix (furosemide injection), which is indicated for the treatment of edema in adult patients with chronic he ...

Powered by passion. Driven by patient care. Corporate Presentation Disclaimer This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our anticipated financial results of the fiscal quarter and full year ended December 31, 2024; our commerc ...

Core Insights - The article discusses the investment position of SCPH, indicating a beneficial long position in the shares of the company [1] Group 1 - The analyst expresses personal opinions regarding SCPH and clarifies that no compensation is received for the article, aside from Seeking Alpha [1] - There is an emphasis on the importance of conducting due diligence and consulting with investment professionals before making trades [2] - The article highlights that past performance is not indicative of future results, and opinions expressed may not reflect the views of Seeking Alpha as a whole [3]